Robert Klafter, MD
Hematology & Oncology · Stockbridge, GANPI 1558360446
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in GA, where the typical reported total is $4,479.
Across 72 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$178
- Pfizer$175
- Merck$173
- Sanofi$162
- Gilead$89
- Johnson & Johnson$85
- plus $604 from 18 others
What the payments were for
- Food & beverage$1,45299%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 10 | $178 |
| Pfizer | 10 | $175 |
| Merck | 7 | $173 |
| Sanofi | 8 | $162 |
| Gilead | 4 | $89 |
| Johnson & Johnson | 4 | $85 |
| Deciphera Pharmaceuticals Inc. | 4 | $84 |
| Pharmacosmos Therapeutics Inc. | 2 | $78 |
| Bayer | 2 | $52 |
| AbbVie | 2 | $52 |
| GSK | 2 | $39 |
| Array Biopharma Inc | 4 | $39 |
| Mirati Therapeutics, Inc. | 2 | $33 |
| ADC Therapeutics America, Inc. | 1 | $31 |
| Tersera Therapeutics LLC | 1 | $27 |
| Astellas Pharma US Inc | 1 | $27 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Novartis | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Exelixis Inc. | 1 | $16 |
| Geron Corporation | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
How this compares
$1,465 in reported general payments places this provider in the 30th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 11 | $252,162 |
| Anastrozole | 24 | $552 |
| Hydroxyurea | 14 | $210 |
| Dexamethasone | 17 | $152 |
| Ondansetron Hcl | 13 | $99 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Stockbridge
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
- Abdullah KutlarAugusta$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.